About
Copy Link
Titles
Research Assistant 1 HSS
Biography
Geena received a bachelor's degree in Psychology from Brown University. While pursuing her bachelor's, she complemented her studies by pursuing clinical work within programs focusing on schizophrenia, mood disorders, and addiction. Geena is currently a postgraduate associate in Anticevic Lab at Yale University School of Psychiatry.
Last Updated on October 07, 2024.
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Geena Fram's published research.
Publications Timeline
A big-picture view of Geena Fram's research output by year.
Terence Ching, PhD
Benjamin Kelmendi, MD
Christopher Pittenger, MD, PhD
John Krystal, MD
Nicole Popp Santamauro, MA
Rachael Grazioplene
Former YSM
8Publications
52Citations
Publications
2026
Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol
Wilkinson S, Prashad S, Dalthorp R, Harding L, Kitay B, Parikh S, Dziura J, Clayton A, Fram G, Lepoutre V, Brown J, Ostroff R, Sanacora G. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol. Contemporary Clinical Trials 2026, 164: 108273. PMID: 41780747, DOI: 10.1016/j.cct.2026.108273.Peer-Reviewed Original ResearchCitations
2025
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial
Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam A, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray D, Grinband J, Gur R, Haubold N, Heffernan Z, Heneks M, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro N, Schutte C, Selloni A, Van Snellenberg J, Surti T, Wolf D, Zharyy C, Group T, Abi-Dargham A, Gur R, Lieberman J, Kantrowitz J, Anticevic A, Cho Y, Krystal J. A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial. Journal Of Psychiatric Research 2025, 194: 196-210. PMID: 41519104, PMCID: PMC13138834, DOI: 10.1016/j.jpsychires.2025.12.020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAcute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Ching T, Stahnke B, Shnayder S, Agin-Liebes G, Adams T, Amoroso L, Baiz O, Belser A, Bohner C, Burke M, D’Amico E, DePalmer G, Eilbott J, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Purohit P, Schaer H, Sierra Y, Witherow C, Pittenger C, Kelmendi B. Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis. Frontiers In Psychiatry 2025, 16: 1726818. PMID: 41450831, PMCID: PMC12728583, DOI: 10.3389/fpsyt.2025.1726818.Peer-Reviewed Original ResearchThis study investigates the effects of single-dose psilocybin on treatment-resistant obsessive-compulsive disorder, finding symptom reductions linked to insights, emotional shifts, and improved psychological flexibility.
2024
Sexual orientation-themed obsessive-compulsive disorder in a lesbian woman: Phenomenology and implications for affirmative assessment and treatment
Schild S, Moore A, Mattera E, Fitzpatrick M, Entezar T, Fram G, Ching T. Sexual orientation-themed obsessive-compulsive disorder in a lesbian woman: Phenomenology and implications for affirmative assessment and treatment. Psychiatry Research Case Reports 2024, 3: 100211. DOI: 10.1016/j.psycr.2024.100211.Peer-Reviewed Original ResearchCitationsAltmetricCorrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Commentaries, Editorials and LettersSafety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Illness Phase as a Key Assessment and Intervention Window for Psychosis
Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitations
2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Copy Link
Contacts
Email